Perrigo Kept 2026 Guidance-But This Turnaround Still Has to Pass the Smell Test

Perrigo's 2026 guidance held, but the market rewarded defense first

Investors responded to guidance retention more than to revenue strength

Perrigo reported adjusted EPS of $0.43, a 30% beat versus estimates, while revenue of $969 million missed the roughly $1.03 billion consensus. The stock still gained 4.73% to $12.19 in premarket trading as investors rewarded management for protecting margins and reaffirming full-year guidance. The message was simple: the market paid for resilience, not yet for a clear turnaround.

Cost discipline can buy time, but it is not demand

That reaction is understandable, but it is still far from proof of a recovery. In 2025, Perrigo still finished with 2025 organic net sales down 2.4%. This quarter did not overcome that weak backdrop; it showed that the company can limit further damage.

Bulls can reasonably argue that holding guidance in a soft OTC environment matters, especially with management pointing to second half improvement. Bears will counter that the core issue remains demand, not execution discipline.

That leaves one central question: can savings buy enough time for consumption to recover?

Perrigo's share gains are real, but category demand is still the test

Shelf strength is visible across U.S. Store Brand and Specialty Care

One signpost still matters: product strength is not the same as consumer demand. A company can have respectable brands and still disappoint investors if overall consumption stays weak.

By the numbers, though, Perrigo still looks operationally healthy in key areas. In the U.S., Store Brand OTC volume share increased 270 basis points, with six of seven categories gaining share. That suggests the company is executing well against retailers and taking volume from competitors.

The same pattern shows up elsewhere. Specialty Care achieved net sales and segment operating income growth, showing that at least one segment is delivering both revenue and profit expansion, not just cost control. Management also highlighted momentum in women's health, consistent with earlier emphasis on Opill.

The demand story is still unresolved

The weak side of the picture is just as important. CORE Net Sales -- Declined 8.3%, primarily due to lower category consumption in Self Care and retailer destocking; nearly two-thirds of the decline attributed to these factors. That is the key distinction. Share gains mean Perrigo is winning against rivals; softer consumption and destocking mean the overall pie is shrinking.

Management has also warned about potential impacts from retailer inventory destocking, and last year's full-year results still included soft total OTC category consumption. That keeps both cases alive:

• Bull case: if consumption stabilizes, Perrigo's share gains can turn into much better sales quickly.
• Bear case: a company can look better than its category and still post weak revenue.

For now, that is the clearest way to read the setup. The brands and operating execution look credible. The demand test is not passed yet.